XML 48 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial Instruments
9 Months Ended
Sep. 30, 2018
Investments, Debt and Equity Securities [Abstract]  
Financial Instruments
Financial Instruments
The following table summarizes our financial assets with maturities of less than 90 days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:
(In millions)
As of
September 30,
2018
 
As of
December 31,
2017
Commercial paper
$
125.3

 
$
30.5

Overnight reverse repurchase agreements
23.7

 
3.6

Money market funds
1,695.1

 
948.0

Short-term debt securities
56.8

 
247.3

Total
$
1,900.9

 
$
1,229.4


The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities.
Upon the adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:
As of September 30, 2018 (In millions)
Fair
Value
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Amortized
Cost
Corporate debt securities
 
 
 
 
 
 
 
Current
$
1,273.7

 
$
0.1

 
$
(0.4
)
 
$
1,274.0

Non-current
677.9

 
0.5

 
(0.8
)
 
678.2

Government securities
 
 
 
 
 
 
 
Current
767.9

 

 
(0.5
)
 
768.4

Non-current
293.0

 

 
(0.6
)
 
293.6

Mortgage and other asset backed securities
 
 
 
 
 
 
 
Current
0.1

 

 

 
0.1

Non-current
273.6

 
0.1

 
(0.6
)
 
274.1

Total marketable debt securities
$
3,286.2

 
$
0.7

 
$
(2.9
)
 
$
3,288.4

Marketable equity securities, non-current
$
624.8

 
$
132.6

 
$
(4.4
)
 
$
496.6

As of December 31, 2017 (In millions)
Fair
Value
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Amortized
Cost
Corporate debt securities
 
 
 
 
 
 
 
Current
$
1,039.3

 
$

 
$
(0.2
)
 
$
1,039.5

Non-current
1,570.5

 
0.9

 

 
1,569.6

Government securities
 
 
 
 
 
 
 
Current
1,075.1

 
0.1

 
(0.7
)
 
1,075.7

Non-current
844.2

 
0.2

 
(1.1
)
 
845.1

Mortgage and other asset backed securities
 
 
 
 
 
 
 
Current
0.8

 

 

 
0.8

Non-current
642.6

 
1.1

 
(0.8
)
 
642.3

Total marketable debt securities
$
5,172.5

 
$
2.3

 
$
(2.8
)
 
$
5,173.0

Marketable equity securities, non-current
$
11.8

 
$
1.8

 
$
(4.4
)
 
$
14.4


Summary of Contractual Maturities: Available-for-Sale Securities
The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:
 
As of September 30, 2018
 
As of December 31, 2017
(In millions)
Estimated
Fair Value
 
Amortized
Cost
 
Estimated
Fair Value
 
Amortized
Cost
Due in one year or less
$
2,041.7

 
$
2,042.5

 
$
2,115.2

 
$
2,116.0

Due after one year through five years
1,111.2

 
1,112.3

 
2,730.0

 
2,730.0

Due after five years
133.3

 
133.6

 
327.3

 
327.0

Total available-for-sale securities
$
3,286.2

 
$
3,288.4

 
$
5,172.5

 
$
5,173.0


The average maturity of our marketable debt securities available-for-sale as of September 30, 2018 and December 31, 2017, was approximately 11 months and 17 months, respectively.
Proceeds from Marketable Debt Securities
The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2018
 
2017
 
2018
 
2017
Proceeds from maturities and sales
$
1,192.0

 
$
888.1

 
$
7,994.7

 
$
4,472.6

Realized gains
$
0.4

 
$
0.3

 
$
3.0

 
$
2.7

Realized losses
$
(0.6
)
 
$
(1.2
)
 
$
(10.8
)
 
$
(4.4
)

Strategic Investments
As of September 30, 2018 and December 31, 2017, our strategic investment portfolio was comprised of investments totaling $687.8 million and $85.8 million, respectively, which are included in investments and other assets in our condensed consolidated balance sheets. The increase in our strategic investment portfolio is a result of our investment in Ionis' common stock, as discussed below.
Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and venture capital funds where the underlying investments are in equity securities of certain biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 marketable equity securities within our disclosures included in Note 7, Fair Value Measurements, to these condensed consolidated financial statements. Our investment in Ionis' common stock will be regularly measured and carried at fair value and classified as a Level 2 marketable equity security within our disclosures in Note 7, Fair Value Measurements, to these condensed consolidated financial statements.
Ionis Pharmaceuticals, Inc.
In June 2018 we closed a new ten-year exclusive agreement with Ionis to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases for a total payment of $1.0 billion consisting of an upfront payment of $375.0 million and the purchase of approximately 11.5 million shares of Ionis' common stock at a cost of $625.0 million.
Our investment in Ionis' common stock is remeasured each reporting period and carried at fair value. The effects of the holding period restrictions are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends.
For additional information on our new agreement with Ionis, please read Note 17, Collaborative and Other Relationships, to these condensed consolidated financial statements.